Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.
The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral eradication rates are pushing 100% for many HCV-infected populations, including patients with HIV/HCV coinfection, decompensated cirrhosis, liver and kidney transplants, and end-stage liver disease. We highlight the greatest successes of combination DAA therapies, discuss the ongoing challenges, and identify the remaining patient subgroups with unmet medical needs.
Duke University School of Medicine and Duke Clinical Research Institute, Durham, North Carolina 27715; email: susanna.naggie@duke.edu.
Susanna
S
Naggie
Duke University School of Medicine and Duke Clinical Research Institute, Durham, North Carolina 27715; email: susanna.naggie@duke.edu.
Andrew J
AJ
Muir
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination / Q000379:methods; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery / Q000821:virology; D008103:Liver Cirrhosis / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation; D012008:Recurrence; D055502:Secondary Prevention / Q000379:methods; D017211:Treatment Failure
D000998:Antiviral Agents
HCV, direct-acting antiviral, HIV/HCV coinfection; decompensated cirrhosis, liver transplant; end-stage liver disease; kidney transplant